Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar warrenout (99.36) Submitted: 8/19/2012 1:13:46 PM : Outperform Start Price: $4.36 EXEL Score: +3.97

EXEL has a large pipeline, with one fast tracked. IMHO this stock doubles by the end of January.

Featured Broker Partners


Advertisement